ReNeuron Group plc Appointment of Joint Broker (2550Q)
25 February 2021 - 6:00PM
UK Regulatory
TIDMRENE
RNS Number : 2550Q
ReNeuron Group plc
25 February 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Appointment of Joint Broker
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces the appointment
of Allenby Capital Limited ("Allenby") as joint corporate broker,
with immediate effect to work alongside the Company's existing
nominated adviser and joint broker, Stifel Nicolaus Europe
Limited.
Michael Hunt, Chief Financial Officer of ReNeuron, commented:
"The Company is pleased to appoint Allenby as its joint corporate
broker, which, together with the appointment of Walbrook PR as the
Company's new investor relations and PR adviser, will further
broaden our investor outreach activities, particularly with regards
to private client brokers and retail investors."
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer Via Walbrook PR
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking) +44 (0)20 3328 5656
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus, Alice Woodings +44 (0)7980 541 893 / +44 (0)7407
804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. he Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPQZLFLFLLEBBV
(END) Dow Jones Newswires
February 25, 2021 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024